174 related articles for article (PubMed ID: 37404599)
1. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
Nashi M; Kishimoto H; Kobayashi M; Tachibana A; Suematsu M; Fujiwara S; Ota Y; Hashitani S; Shibatsuji T; Nishida T; Fujimura K; Furudoi S; Ishida Y; Ishii S; Fujita T; Iwai S; Shigeta T; Harada T; Miyai D; Takeda D; Akashi M; Noguchi K; Takenobu T
J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
[TBL] [Abstract][Full Text] [Related]
2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
3. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.
Aoki K; Matsunaga S; Ito S; Shibahara T; Nomura T; Matsuzaki H; Abe S; Yamaguchi A
J Bone Miner Metab; 2021 Sep; 39(5):737-747. PubMed ID: 33830351
[TBL] [Abstract][Full Text] [Related]
4. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
Aljohani S; Gaudin R; Weiser J; Tröltzsch M; Ehrenfeld M; Kaeppler G; Smeets R; Otto S
J Craniomaxillofac Surg; 2018 Sep; 46(9):1515-1525. PubMed ID: 29983309
[TBL] [Abstract][Full Text] [Related]
6. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
Taguchi A; Shiraki M; Morrison A; Khan AA
Osteoporos Sarcopenia; 2017 Jun; 3(2):64-74. PubMed ID: 30775507
[TBL] [Abstract][Full Text] [Related]
7. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication).
Baba A; Ojiri H; Goto TK; Ikeda K; Yamauchi H; Ogino N; Mogami T
Jpn Dent Sci Rev; 2019 Nov; 55(1):58-64. PubMed ID: 30815046
[TBL] [Abstract][Full Text] [Related]
8. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
Takaoka K; Kishimoto H
Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
[TBL] [Abstract][Full Text] [Related]
9. Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw.
Assaf AT; Zrnc TA; Remus CC; Adam G; Zustin J; Heiland M; Friedrich RE; Derlin T
J Craniomaxillofac Surg; 2015 Oct; 43(8):1461-9. PubMed ID: 26232916
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
; Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Nagata T; Urade M; Shibahara T; Toyosawa S
J Bone Miner Metab; 2017 Jan; 35(1):6-19. PubMed ID: 28035494
[TBL] [Abstract][Full Text] [Related]
11. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
Shibahara T
Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
[TBL] [Abstract][Full Text] [Related]
12. Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.
Hasegawa T; Ueda N; Yamada SI; Kato S; Iwata E; Hayashida S; Kojima Y; Shinohara M; Tojo I; Nakahara H; Yamaguchi T; Kirita T; Kurita H; Shibuya Y; Soutome S; Akashi M;
Osteoporos Int; 2021 Nov; 32(11):2323-2333. PubMed ID: 33997909
[TBL] [Abstract][Full Text] [Related]
13. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice.
Hayano H; Kuroshima S; Sasaki M; Tamaki S; Inoue M; Ishisaki A; Sawase T
Bone; 2020 Jun; 135():115308. PubMed ID: 32142911
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
[TBL] [Abstract][Full Text] [Related]
15. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study.
Pichardo SEC; Broek FWT; Fiocco M; Appelman-Dijkstra NM; van Merkesteyn JPR
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Apr; 129(4):411-417. PubMed ID: 32001241
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
[TBL] [Abstract][Full Text] [Related]
19. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
[TBL] [Abstract][Full Text] [Related]
20. Preventive Effects of Dental Pulp Stem Cell-conditioned Media on Anti-RANKL Antibody-Related Osteonecrosis of the Jaw.
Kaminogo K; Yamaguchi S; Chen H; Yagita H; Toyama N; Urata Y; Hibi H
Calcif Tissue Int; 2024 May; ():. PubMed ID: 38809297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]